Y-mAbs Therapeutics, Inc. Stock

$4.31

0.23% yesterday

Nasdaq, Jul 18, 10:00 pm CET

ISIN

US9842411095

Symbol

YMAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Y-mAbs Therapeutics, Inc. Stock price

$4.31

-36.58 89.46% 5Y

Nasdaq, Closing price Fri, Jul 18 2025

-0.01 0.23%

ISIN

US9842411095

Symbol

YMAB

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$195.2m

Enterprise Value

$134.9m

Net debt

positive

Cash

$60.3m

Shares outstanding

45.3m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

2.2 | 2.3

EV/Sales

1.5 | 1.6

EV/FCF

negative

P/B

2.2

Financial Health

Equity Ratio

76.7%

Return on Equity

-32.2%

ROCE

-32.9%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$88.7m | $84.1m

EBITDA

$-30.4m | $-51.5m

EBIT

$-30.8m | $-47.8m

Net Income

$-28.2m | $-45.5m

Free Cash Flow

$-19.3m

Growth (TTM | estimate)

Revenue

4.9% | -4.1%

EBITDA

-24.8% | -76.7%

EBIT

-23.0% | -61.2%

Net Income

-30.3% | -53.4%

Free Cash Flow

-9.6%

EPS

$-0.6

FCF per Share

$-0.4

Short interest

6.9%

Employees

104

Rev per Employee

$840.0k

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Get Started for Free Today

Y-mAbs Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

??

17 Analysts have issued a Y-mAbs Therapeutics, Inc. forecast:

14x Buy

82%

More details on Analyst Estimates Including Price Targets

17 Analysts have issued a Y-mAbs Therapeutics, Inc. forecast:

Buy

82%

Hold

Sell

12%

Analyst Estimates with Stock Price Targets

Financial data from Y-mAbs Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	89 89	5% 5% 100%
- Direct Costs	16 16	40% 40% 18%
Gross Profit	73 73	1% 1% 82%
- Selling and Administrative Expenses	56 56	27% 27% 63%
- Research and Development Expense	46 46	15% 15% 52%
EBITDA	-30 -30	25% 25% -34%
- Depreciation and Amortization	0.45 0.45	37% 37% 1%
EBIT (Operating Income) EBIT	-31 -31	23% 23% -35%
Net Profit	-28 -28	30% 30% -32%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Y-mAbs Therapeutics, Inc. Stock News

Neutral

GlobeNewsWire

●

about 2 months ago

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

PRINCETON, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radiopharmaceuticals, and commercial stage antibody-based therapeutic products for the treatment of cancer, today announced that the Company plans to highlight progress acros...

Neutral

GlobeNewsWire

●

about 2 months ago

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

PRINCETON, N.J., May 26, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of GD2-SADA in recurrent or refractory metastatic sol...

Neutral

Seeking Alpha

●

2 months ago

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Courtney Dugan - Vice President, Head of Investor Relations Michael Rossi - President and Chief Executive Officer Doug Gentilcore - DANYELZA Business Unit Head Peter Pfreundschuh - Chief Financial Officer Conference Call Participants Nicole Germino - Truist Securities Mike Ulz ...

More Y-mAbs Therapeutics, Inc. News

Company Profile

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Head office	United States
CEO	Michael Rossi
Employees	104
Founded	2015
Website	www.ymabs.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now